Clinical Trials List
2025-12-15 - 2028-06-29
Phase I/II
Recruiting3
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 莊建淮 無
- YU-YUN SHAO 無
- TSUNG-HAO LIU 無
- 呂理駿 無
- Chih-Hung Hsu 無
- 陳柏邑 無
- Chiun Hsu 無
- Ying-Chun Shen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yih-Jyh Lin 無
- Liu Yi-Sheng 無
- Chiu Hung Chiu 無
- Hsin-Yu Kuo 無
- 邱彥程 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 齊振達 無
- San-Chi Chen 無
- 吳啟榮 無
- Pei-Chang Lee 無
- Hung-Yuan Yu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
129 participants
